Protagonist Therapeutics PTGX Increase (Decrease) in Contract with Customer, Asset

Increase (Decrease) in Contract with Customer, Asset at other companies

T-Mobile USTMUS

$61M-23.8%

Rocket Lab USA, Inc.RKLB

$13.43M+721%

Northrop GrummanNOC

$551M-48.5%

Bloom EnergyBE

$64.69M+4,292%

Ionis PharmaceuticalsIONS

$7.63M+115%

GE HealthCare TechnologiesGEHC

$46M+188%

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's increase (decrease) in contract with customer, asset.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's increase (decrease) in contract with customer, asset?: Protagonist Therapeutics (PTGX) reported increase (decrease) in contract with customer, asset of $22.83M in Q1 2025.